Stockscreener 앱 받기
14.31
3.44%
-0.51
전일 마감가:
$14.82
열려 있는:
$14.82
하루 거래량:
2.09M
Relative Volume:
1.27
시가총액:
$1.28B
수익:
$-249.00K
순이익/손실:
$-187.60M
주가수익비율:
-5.724
EPS:
-2.5
순현금흐름:
$-201.88M
1주 성능:
-5.67%
1개월 성능:
+6.16%
6개월 성능:
+182.81%
1년 성능:
+188.51%
1일 변동 폭
$13.88
$15.07
1주일 범위
$13.88
$16.96
52주 변동 폭
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.31 | 1.63B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Trend analysis for Amylyx Pharmaceuticals Inc. this weekJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); ... - Bluefield Daily Telegraph
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - Eastern Progress
Using flow based indicators on Amylyx Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - newser.com
What’s the recovery path for long term holders of Amylyx Pharmaceuticals Inc.July 2025 Setups & Expert Curated Trade Setups - newser.com
Will Amylyx Pharmaceuticals Inc. price bounce be sustainableTrade Analysis Summary & Community Verified Swing Trade Signals - newser.com
Amylyx gets FDA fast track status for ALS treatment - MSN
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. t - GuruFocus
Measuring Amylyx Pharmaceuticals Inc.’s beta against major indices2025 Price Targets & Technical Pattern Based Buy Signals - newser.com
Will Amylyx Pharmaceuticals Inc. continue its uptrendTrade Exit Summary & Technical Pattern Based Buy Signals - newser.com
Tools to monitor Amylyx Pharmaceuticals Inc. recovery probabilityJuly 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
Using economic indicators to assess Amylyx Pharmaceuticals Inc. potential2025 Volume Leaders & Daily Price Action Insights - newser.com
Published on: 2025-10-20 22:38:43 - newser.com
Important Notice to Long-Term Shareholders of Amylyx - GlobeNewswire
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceWeekly Trade Analysis & Consistent Income Trade Recommendations - newser.com
Why Amylyx Pharmaceuticals Inc. stock attracts global investorsWeekly Trend Report & Daily Profit Focused Stock Screening - newser.com
How the Class Action Investigation Into Relyvrio Disclosures at Amylyx Pharmaceuticals (AMLX) Has Changed Its Investment Story - Sahm
How Amylyx Pharmaceuticals Inc. stock benefits from global expansionRecession Risk & Advanced Technical Signal Analysis - nchmf.gov.vn
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth buildingPortfolio Gains Summary & Reliable Price Breakout Alerts - newser.com
How supply chain issues affect Amylyx Pharmaceuticals Inc. stockPortfolio Return Report & Scalable Portfolio Growth Methods - nchmf.gov.vn
Growth Value: Why Amylyx Pharmaceuticals Inc. stock attracts global investorsBull Run & High Yield Equity Trading Tips - nchmf.gov.vn
Is Amylyx Pharmaceuticals Inc. stock a top pick in earnings seasonInsider Buying & Expert Approved Momentum Ideas - nchmf.gov.vn
Aug Swings: Is Amylyx Pharmaceuticals Inc. stock a top pick in earnings seasonQuarterly Trade Summary & Low Risk Profit Maximizing Plans - nchmf.gov.vn
Volatility Watch: Will Amylyx Pharmaceuticals Inc. stock beat EPS estimates2025 Technical Overview & Free Real-Time Market Sentiment Alerts - nchmf.gov.vn
Amylyx Pharmaceuticals (AMLX): Assessing Valuation After Class Action Probe Challenges Relyvrio Demand Claims - Sahm
Will Amylyx Pharmaceuticals Inc. stock beat EPS estimatesShort Setup & Weekly Top Performers Watchlists - nchmf.gov.vn
Exit Recap: Is Amylyx Pharmaceuticals Inc. stock affected by interest rate hikesGold Moves & Expert Curated Trade Setups - nchmf.gov.vn
Oklahoma City NewsThe Oklahoman - FinancialContent
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Assessing the 15.36% Upside Potential and Strong Analyst Ratings - DirectorsTalk Interviews
Is AMLX Stock a Solid Choice Right Now? - sharewise.com
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges - GlobeNewswire
About Us - FinancialContent
Baird Maintains Amylyx Pharmaceuticals (AMLX) Outperform Recommendation - Nasdaq
How institutional ownership impacts Amylyx Pharmaceuticals Inc. stockWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Amylyx Pharmaceuticals prices $175M public offering - MSN
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.17%
자본화:
|
볼륨(24시간):